Clinical Trial Update: Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on the efficacy and safety of Vascana in subjects with Raynaud's phenomenon secondary to connective tissue disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Connective Tissue Disease
• Raynaud Phenomenon

Drugs mentioned

• Vascana

Snippet

Sponsor: Covis Pharma S.à.r.l. | Conditions: Raynaud's Phenomenon Secondary to Connective Tissue Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-11-02